Table 3.
Neutralising antibody immune responses to homologous and heterologous H5N1 influenza strains following one or two doses of the AS03A-adjuvanted A/Indonesia/5/2005 (H5N1) influenza vaccine in terms of seropositivity rates and seroconversion rates.
| Antibody | Time point | N | Seropositivity % (95% CI) | N | Seroconversion % (95% CI) |
|---|---|---|---|---|---|
| A/Indonesia | PRE | 99 | 11.1 (5.7-19.0) | -- | -- |
| Day 42 | 100 | 100 (96.4-100) | 99 | 97.0 (91.4-99.4) | |
| Day 182 | 99 | 100 (96.3-100) | 98 | 93.9 (87.1-97.7) | |
| A/Vietnam | PRE | 100 | 50.0 (39.8-60.2) | -- | -- |
| Day 42 | 100 | 95.0 (88.7-98.4) | 100 | 47.0 (36.9-57.2) | |
| Day 182 | 99 | 92.9 (86.0-97.1) | 99 | 58.6 (48.2-68.4) | |
Subjects received one dose of vaccine on Day 0 and one dose on Day 21 (ATP cohort for immunogenicity and persistence).
Seroconversion rate for MN antibodies: Percentage of subjects with at least four-fold increase post-vaccination neutralising antibody titres.